ReviewMicrobial cell factories2014
Engineering Escherichia coli to overproduce aromatic amino acids and derived compounds.
Review in Microbial cell factories, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed.
- Adaptive Laboratory Evolution inMicroorganisms · 2026Review
- A non-classical biosynthetic route enables tocopherol synthesis in bacteria.Nature metabolism · 2026Article
- A Comprehensive Review on the Pharmacological Activities and Biosynthetic Strategies of Protocatechuic Acid.Life (Basel, Switzerland) · 2026Review
- Combinatorial optimization engineering for the high-level production of shikimic acid in Escherichia coli.Microbial cell factories · 2026Article
- Theranostic Probiotic Engineered Living Materials That Dynamically Respond to Inflammation Markers.Advanced healthcare materials · 2026Article
- Metabolic engineering ofApplied and environmental microbiology · 2025Article
- In silico identification of gene targets to enhance C12 fatty acid production in Escherichia coli.Applied microbiology and biotechnology · 2025Article
- Aromatic Amino Acids: Exploring Microalgae as a Potential Biofactory.Biotech (Basel (Switzerland)) · 2025Review
- Advances in the Study of Halogenated Natural Products.Current topics in medicinal chemistry · 2025Review
- Expanding the application of tyrosine: engineering microbes for the production of tyrosine and its derivatives.Frontiers in bioengineering and biotechnology · 2025Review
- Metabolic engineering strategies for L-Homoserine production in Escherichia coli.Microbial cell factories · 2024Review
- Stability of a MutualisticEngineering in life sciences · 2024Article
- The β-subunit of tryptophan synthase is a latent tyrosine synthase.Nature chemical biology · 2024Article
- A modular and synthetic biosynthesis platform for de novo production of diverse halogenated tryptophan-derived molecules.Nature communications · 2024Article
- Rational strain design with minimal phenotype perturbation.Nature communications · 2024Article
- Improved lipid production and component of mycosporine-like amino acids by co-overexpression of amt1 and aroB genes in Synechocystis sp. PCC6803.Scientific reports · 2023Article
- An Efficient Prephenate Dehydrogenase Gene for the Biosynthesis of L-tyrosine: Gene Mining, Sequence Analysis, and Expression Optimization.Foods (Basel, Switzerland) · 2023Article
- A tripartite microbial co-culture system for de novo biosynthesis of diverse plant phenylpropanoids.Nature communications · 2023Article
- Engineered Escherichia coli platforms for tyrosine-derivative production from phenylalanine using phenylalanine hydroxylase and tetrahydrobiopterin-regeneration system.Biotechnology for biofuels and bioproducts · 2023Article
- Engineering Escherichia coli to Utilize Erythritol as Sole Carbon Source.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The production of aromatic amino acids using fermentation processes with recombinant microorganisms can be an advantageous approach to reach their global demands. In addition, a large array of compounds with alimentary and pharmaceutical applications can potentially be synthesized from intermediates of this metabolic pathway. However, contrary to other amino acids and primary metabolites, the artificial channelling of building blocks from central metabolism towards the aromatic amino acid pathway is complicated to achieve in an efficient manner. The length and complex regulation of this pathway have progressively called for the employment of more integral approaches, promoting the merge of complementary tools and techniques in order to surpass metabolic and regulatory bottlenecks. As a result, relevant insights on the subject have been obtained during the last years, especially with genetically modified strains of Escherichia coli. By combining metabolic engineering strategies with developments in synthetic biology, systems biology and bioprocess engineering, notable advances were achieved regarding the generation, characterization and optimization of E. coli strains for the overproduction of aromatic amino acids, some of their precursors and related compounds. In this paper we review and compare recent successful reports dealing with the modification of metabolic traits to attain these objectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.